Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Phase 2 Completed
34 enrolled 22 charts
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Phase 2 Completed
53 enrolled 17 charts
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase 1/2 Completed
46 enrolled
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
Phase 2 Completed
261 enrolled 10 charts
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
Phase 1/2 Completed
127 enrolled 18 charts
AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia
Phase 1 Completed
18 enrolled
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase 2 Completed
53 enrolled 11 charts
AZD2171 to Treat Prostate Cancer
Phase 2 Completed
59 enrolled 12 charts
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
Phase 2 Completed
74 enrolled 11 charts
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Phase 2 Completed
24 enrolled 12 charts
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
Phase 2 Completed
22 enrolled 23 charts
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
Phase 2 Completed
60 enrolled 8 charts
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
Phase 2 Completed
54 enrolled 12 charts
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 Completed
39 enrolled 9 charts
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Phase 1 Completed
55 enrolled
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
Phase 2 Completed
44 enrolled 8 charts
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
Phase 2 Completed
26 enrolled 9 charts
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Phase 2 Completed
47 enrolled 15 charts
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
Phase 2 Completed
6 enrolled
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
Phase 1 Completed
47 enrolled
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
20 enrolled
AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
Phase 2 Completed
25 enrolled 5 charts
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase 2 Completed
51 enrolled 5 charts
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase 1 Completed
57 enrolled
Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery
Phase 2 Completed
130 enrolled
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 2 Completed
31 enrolled
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
Phase NA Completed
33 enrolled
Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase 2 Completed
44 enrolled
AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Phase 2 Completed
35 enrolled